Buprenorphine (Suboxone, Sublocade) prior authorization at Humana
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Humana requires prior-authorization documentation for Buprenorphine (Suboxone, Sublocade): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Humana reviews Buprenorphine (Suboxone, Sublocade) prior authorizations against its medical policy . Humana-specific context: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Humana's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- MA plan step therapy on Part B drugs
- Skilled nursing facility days
- Prior auth on specialty drugs
- OON emergency reduction
Buprenorphine (Suboxone, Sublocade)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring sublingual before long-acting injectable
- Specialty pharmacy restriction
- Frequency reduction
Marketed as Suboxone, Subutex (sublingual), Sublocade (monthly injectable), Brixadi (weekly/monthly injectable). Federal Medicaid required coverage.
Manufacturer patient-assistance program: Indivior INSUPPORT — relevant when a Humana denial sticks and the patient needs bridge access while appealing.
How Humana approaches Medications for Opioid Use Disorder (MOUD) PAs
For Buprenorphine, check whether the current Humana Medications for Opioid Use Disorder (MOUD) policy cites prior auth on specialty drugs. Pharmacy-benefit review for Buprenorphine at Humana is routed through Humana Pharmacy Solutions (in-house, Medicare Advantage-focused). The applicable review clock depends on the member's current product, whether the request is complete and urgent, and governing plan rules. Confirm receipt and timing with Humana; if denied, use the filing date and route printed on that denial notice. MHPAEA non-quantitative-treatment-limitation analysis applies — request Humana's written NQTL comparative analysis under the 2023 final rule when the MOUD denial appears stricter than comparable medical-side prior auth. Humana is domiciled in KY, so unresolved appeals escalate to the KY insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead).
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.humana.com/provider) with the same packet plus an applicable, current clinical source supporting Buprenorphine (Suboxone, Sublocade)for the patient's indication.
Medicare Advantage cases may have plan reconsideration and independent-review steps. Confirm the current level, forwarding rule, and any expedited pathway directly in the notice before selecting an escalation route.
Humana Medicare Advantage organization determinations operate under 42 CFR Part 422 Subpart D. For Buprenorphine, the Part B vs Part D coverage determination is the threshold question — Part B drugs (provider-administered) follow the organization-determination track under 42 CFR §422.566, while Part D drugs follow the coverage-determination track under 42 CFR §423.566. The applicable decision period and any Independent Review Entity routing depend on the request type, current rule, and plan notice. Record the cited source and version, then verify the operational due date against the current notice and CMS materials before relying on it.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Humana denial on DenialHelp.
Contact Humana
- Provider portal: https://www.humana.com/provider
Frequently asked questions
What documentation does Humana need for Buprenorphine (Suboxone, Sublocade) prior auth?
Humana's typical PA packet for Buprenorphine (Suboxone, Sublocade): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Humana?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for Buprenorphine (Suboxone, Sublocade) at Humana?
Preparation scenarios to check against the current notice and policy include: MA plan step therapy on Part B drugs; Skilled nursing facility days; Prior auth on specialty drugs. These are not measured frequency claims. For Buprenorphine (Suboxone, Sublocade), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
Can Humana apply step therapy to MOUD like Buprenorphine?
MHPAEA prohibits non-quantitative treatment limitations on MOUD that are stricter than the limits on comparable medical/surgical benefits. Request Humana's written NQTL comparative analysis under the 2023 MHPAEA final rule. State Medicaid MCO plans are additionally required to cover all FDA-approved MOUD products without step therapy under the SUPPORT Act (2018) and related state plan amendments. Pharmacy-benefit handling is routed through Humana Pharmacy Solutions (in-house, Medicare Advantage-focused). External-review escalation for Humana fully-insured policies sits with the KY insurance department.
How do I prep for a peer-to-peer with Humana on Buprenorphine (Suboxone, Sublocade)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Buprenorphine (Suboxone, Sublocade) PA packet
Open ApprovalHelp — generate a Buprenorphine (Suboxone, Sublocade) prior-auth packet tailored to Humana's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com